Table 3.
Condition | Intervention | Administration | Primary Aim | Phase | Participants | Status | Identifier |
---|---|---|---|---|---|---|---|
aGvHD | FMT | Orally via capsule | Efficacy, safety, and tolerability | I | 10 | NYR | NCT04280471 |
GI aGvHD | FMT | Colonoscopy or gastroscopy | Efficacy and safety | II | 30 | R | NCT03812705 |
GI aGvHD | FMT | Nasojejunal tube | Efficacy and safety | I | 15 | NYR | NCT03549676 |
GI aGvHD | FMT | Orally via capsule | Efficacy and safety | I/II | 20 | R | NCT04269850 |
GI aGvHD | FMT | Orally via capsule | Efficacy and safety | II | 17 | NYR | NCT04059757 |
GI aGvHD | FMT | Colonoscopy or gastroscopy | Efficacy | III | 15 | R | NCT03819803 |
GI aGvHD | FMT | Orally via capsule | Efficacy and safety | N/A | 10 | R | NCT04622475 |
aGvHD | FMT | Orally via capsule | Feasibility and efficacy | I | 11 | NYR | NCT04139577 |
GI aGvHD | FMT | Colonoscopy or duodenal nutrition tube injection | Efficacy | I | 30 | R | NCT04285424 |
Allo-HSCT, AML | FMT | Orally via capsule | Efficacy and incidence of infections | II | 120 | R | NCT03678493 |
AML | FMT | Rectal enema | Evaluation in dysbiosis correction and in MDRB eradication | I/II | 20 | C | NCT02928523 |
aGvHD | FMT | Not specified | Efficacy | II | 24 | C | NCT03359980 |
Allo-HSCT | FMT | Orally via capsule | Feasibility and efficacy | I | 18 | C | NCT02733744 |
Allo-HSCT | Potato-based dietary starch | Orally | Incidence of grade II-IV GVHD | II | 70 | R | NCT02763033 |
Allo-HSCT | Fructo-oligosaccharides prebiotic | Orally | Safety and tolerability | I | 15 | C | NCT02805075 |
Allo-HSCT | Galacto-oligosaccharide prebiotic | Orally | Tolerability and incidence of Grade II-IV aGVHD | I/II | 128 | NYR | NCT04373057 |
Allo-HSCT | Human lysozyme goat milk prebiotic | Orally | Safety and tolerability | I | 36 | NYR | NCT04177004 |
Allo-HSCT | Clostridium butyricum CBM 588 Probiotic Strain | Orally | Safety | I | 36 | R | NCT03922035 |
AML acute myeloid leukemia; Allo-HSCT allogeneic hematopoietic stem cell transplant; FMT fecal microbiota transplant; GI gastrointestinal; GvHD graft versus host disease; HSCT hematopoietic stem cell transplant; MDRB multidrug resistant bacteria; NYR, Not yet recruiting; R recruiting; C completed.